<DOC>
	<DOCNO>NCT00714857</DOCNO>
	<brief_summary>Dexmedetomidine new , highly selective potent alpha2-adrenoreceptor agonist register sedation patient intensive care unit . Although pharmacokinetics dexmedetomidine study previously also ICU set , information pharmacokinetics long-lasting ( &gt; 48 hour ) dexmedetomidine infusion human . The aim study study pharmacokinetics long-lasting dexmedetomidine infusion ICU patient use population pharmacokinetics approach .</brief_summary>
	<brief_title>Population Pharmacokinetics Dexmedetomidine ICU Patients</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Age ≥ 18 year . Need dexmedetomidine sedation ( determine responsible physician ) . Predicted length dexmedetomidine sedation ≥ 48 hour . Written informed consent patient relatives participate patient . A previous history intolerance study drug relate compound additive . Existing significant haematological , endocrine , metabolic gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>ICU patient</keyword>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Sedation</keyword>
	<keyword>Judged</keyword>
	<keyword>Attending</keyword>
	<keyword>Physician</keyword>
</DOC>